FDA Censures Glaxo Over Flawed Avandia Reports
The U.S. Food and Drug Administration has issued a warning letter to GlaxoSmithKline Plc for repeatedly failing to report clinical trials related to its diabetes drug Avandia, which has been tied...To view the full article, register now.
Already a subscriber? Click here to view full article